According to the CDC, obesity-related health care expenditures in the United States total approximately $173 billion annually, with individuals with obesity incurring an average of $1,861 more in medical costs each year than do those at a healthy weight.[27] However, the economic impact extends beyond direct medical spendingobesity also reduces workforce participation and productivity, contributing to an estimated 4.4 percent decline in GDP.[28] As innovative therapies such as GLP-1s offer new hope for addressing obesity, quantifying its broader economic burden helps underscore the value and potential return on investment of such therapeutic advances
La documentacin tcnica de Institute BCN describe la L-carnitina como un compuesto presente de forma natural en el organismo y como un cofactor esencial del metabolismo cido de los lpidos
Three decades of nucleic acid aptamer technologies: lessons learned, progress and opportunities on aptamer development
Future directions The development of oral GLP-1 receptor agonists represents a significant advancement in the management of T2DM
It provides defense against cognitive impairment, acetylcholinesterase activity, oxidative stress, and cytoarchitectural abnormalities caused by aluminum chloride, in addition to potentially improving ASD symptoms by increasing GABA production [156]
